This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes. Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL